News Research The DOM Insider Clinical

Immunotherapy improves survival of patients with locally advanced head and neck cancer

Cardiovascular Division •
An international clinical trial co-led by WashU Medicine found that the immunotherapy drug pembrolizumab added to standard-of-care therapy improved survival for patients with locally advanced head and neck cancer. Pembrolizumab helps the patient’s own immune cells attack and kill tumor cells. Shown is an artist's rendering of immune cells (light blue) attacking a cancer cell. (Image: Getty Images)
View Content

An international phase 3 clinical trial led by Washington University School of Medicine in St. Louis and Dana-Farber Brigham Cancer Center shows that patients with certain locally advanced head and neck cancers benefited from the addition of the immunotherapy drug pembrolizumab (brand name Keytruda) to standard-of-care therapy.